Amgens studieläkemedel olpasiran sänker nivån av lipoprotein(a), en biomarkör med koppling till kardiovaskulär sjukdom, med hela 90 procent. – Ett effektivt och säkert läkemedel vore mycket önskvärt då vi vet att förhöjda nivåer av lipoprotein(a) innebär en ökad risk för hjärt-kärlsjukdom, säger docent Linda Mellbin, kardiolog vid Karolinska Universitetssjukhuset.
Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.se
Gustav III:s Boulevard 54
169 27 Solna
Sverige